Abstract
Benzodiazepines (BDZs) are the most widely prescribed class of psychoactive drugs in current therapeutic use, despite the important unwanted side-effects that they produce such as sedation, myorelaxation, ataxia, amnesia, ethanol and barbiturate potentiation and tolerance. Searching for safer BDZ-receptor (BDZ-R) ligands we have recently demonstrated the existence of a new family of ligands which have a flavonoid structure. First isolated from plants used as tranquilizers in folkloric medicine, some natural flavonoids have shown to possess a selective and relatively mild affinity for BDZ-Rs and a pharmacological profile compatible with a partial agonistic action. In a logical extension of this discovery various synthetic derivatives of those compounds, such as 6,3′-dinitroflavone were found to have a very potent anxiolytic effect not associated with myorelaxant, amnestic or sedative actions. This dinitro compound, in particular, exhibits a high affinity for the BDZ-Rs (Ki = 12–30 nM). Due to their selective pharmacological profile and low intrinsic efficacy at the BDZ-Rs, flavonoid derivatives, such as those described, could represent an improved therapeutic tool in the treatment of anxiety. In addition, several flavone derivatives may provide important leads for the development of potent and selective BDZ-Rs ligands.
Similar content being viewed by others
REFERENCES
Mohler, H., and Okada, T. 1977. Benzodiazepine receptors: demonstration in the central nervous system. Science 198:849–851.
Squires, R. F., and Braestrup, C. 1977. Benzodiazepine receptors in rat brain. Nature 266:732–734.
Mc Kernan, R. M., and Whiting, P. J. 1996. Which GABAA receptors subtypes really occur in the brain? TINS 19:139–143.
Olsen, R. W., and Venter, J. C. 1986. Benzodiazepine/GABA receptors and chloride channels. Structural and Functional Properties. Alan R. Liss, New York.
Mohler, H., Knoflach, F., Paysan, K., Motejlek, K., Benke, D., Luscher, B., and Fritschy, J. M. 1995. Heterogeneity of GABAA receptors: cell-specific expression, pharmacology, and regulation. Neurochem. Res. 20:631–638.
Phillis, J. W., and O'Regan, M. H. 1988. The role of adenosine in the central actions of the benzodiazepines. Prog. Neuropsychopharmacol. & Biol. Psychiat. 12:389–404.
Costa, E., and Guidotti, A. 1996. Benzodiazepines on trial: a research strategy for their rehabilitation. TIPS: 17:192–200.
Siegharth, W., and Karobath, M. 1980. Molecular heterogeneity of benzodiazepine receptors. Nature 285:826–828.
Trifiletti, R. R., Lo, M. M. S., and Snyder, S. H. 1984. Kinetics differences between type I and type II benzodiazepine receptors. Mol. Pharmacol. 26:228–234.
Niddam, R. A., Dubois, A., Scatton, B., Arbilla, S., and Langer, S. Z. 1987. Autoradiographic localization of [3H] zolpidem binding sites in the rat CNS: comparison with the distribution of [3H] flunitrazepam binding sites. J. Neurochem. 49:890–896.
Woods, J. H., Katz, J. L., and Winger, G. 1992. Benzodiazepines: use, abuse and consequences. Pharmacol. Rev. 44:151–347.
Pratt, J. A. 1991. Psychotropic drug tolerance and dependence: common underlying mechanism? Pages 2–28, in The Biological bases of drug tolerance and dependence, Academic Press.
Kales, A., Bixler, E., Vela-Bueno, A., Soldatos, C. R., and Manfredi, R. L. 1987. Alprazolam: effects on sleep and withdrawal phenomena. J. Clin. Pharmacol. 27:508–515.
Miller, L. G., Woolverton, S., Greenblatt, D. J., Lopez, F., Beth Roy R., and Shader, R. 1989. Chronic benzodiazepine administration IV. Biochem Pharmacol. 38:3773–3777.
Gallagher, D., and Primus, R. J. 1992. Benzodiazepine tolerance and dependence: GABAA receptor complex locus of change. Biochem. Soc. Symp. 59:135–151.
Nutt, D. J. 1986. Benzodiazepine dependence in the clinic: reason for anxiety. TIPS 7:457–460.
Griffiths, R. R., and Sannerud, C. A. 1987. Abuse liability of tranquilizers. In Rational use of psychotropic drugs with special emphasis on tranquilizers in non-psychiatric setting. M. E. Vartanian et al. (eds.) pages 23–29, Excerpta Med., Amsterdam.
Rickels, K., Schweizer, E., Case, W. G., and Greenblatt, D. J. 1990. Long-term therapeutic use of benzodiazepines. I. Effect of abrupt discontinuation. Arch. Gen. Psychiat. 47:899–907.
Thiebot, M. H. 1985. Some evidence for amnesic-like effects of benzodiazepines in animals. Neurosci. Biobehav. Rev. 9:95–100.
Izquierdo, I., Pereira, M. E., and Medina, J. H. 1990. Benzodiazepine receptor ligand influences on acquisition: suggestion of an endogenous modulatory mechanism mediated by benzodiazepine receptors. Behav. Neural Biol. 54:27–41.
Lister, R. 1985. The amnestic action of benzodiazepines in man. Neurosci. Biobehav. Rev. 9:87–93.
Izquierdo, I., and Medina, J. H. 1991. GABAA modulation of memory: the role of endogenous benzodiazepines. TIPS 12:260–265.
Haefely, W. E., Martin, J. R., and Schoch, P. 1990. Novel anxiolytics that act as partial agonists at benzodiazepine receptors. TIPS 11:452–456.
Moreau, J. L., Jenck, F., Pieri, L., Schoch, P., Martin, J. R., and Haefely, W. E. 1990. Physical dependence induced in DBA/2j mice by benzodiazepine receptor full agonists, but not by partial agonist Ro 16–6028. Eur. J. Pharmacol. 190:269–273.
Haig, J. R., and Feely, M. Ro, 1988. 16–6028, a benzodiazepine receptor partial agonist, does not exhibit anticonvulsant tolerance in mice. Eur. J. Pharmacol. 147:282–285.
Morton, S., and Lader, M. 1990. Studies with alpidem in normal volunteers and anxious patients. Pharmacopsychiatry. 23:120–123.
Perrault, G., Morel, E., Sanger, D. J., and Zivkovic, B. 1993. Repeated treatment with alpidem, a new anxiolytic, does not induce tolerance or physical dependence. Neuropharmacol. 32:855–863.
Schoch, P., Moreau, J. I., Martin, J. R., and Haefely, W. E. 1992. Aspect of benzodiazepine receptor structure and function with relevance to drug tolerance and dependence. Biochem. Soc. Symp. 59:121–134.
Harborne, J. B. (ed.) 1994. The Flavonoids, Advances in research since 1986. Chapman and Hall, London.
Middleton, E., and Kandaswami, C. 1994. The impact of plant flavonoids on mammalian biology: implications for immunity, inflammation and cancer, Pages 619–645, in Harbone J. B. (ed.) The Flavonoids, Chapman and Hall, London.
Miksicek, R. J. 1993. Commonly occurring plant flavonoids have estrogenic activity. Mol. Pharmacol. 44:37–43.
Barnard, I., Smee, F., Huffman, J. H., Meyerson, L. H. Sidwell, R. W. 1993. Antiherpes virus activity of 59–303, a novel plant flavonoid. Chemother. 39:203–211.
Picq, M., Cheav, S. V., and Prigent, A. F. 1991. Effect of two flavonoid compounds on the central nervous system. Analgesic activity. Life Sci. 49:1979–1988.
Kleinjnen, J., and Knipschild, P. 1992. Ginkgo biloba. Lancet 340:1136–1139.
Oyama, Y., Fuchs, P. A., Katayama, N., and Noa, K. 1994. Myricetin and quercetin, the flavonoid constituents of Ginkgo biloba extract, greatly reduce oxidative metabolism in both resting and Ca(2+)-loaded brain neurons. Brain Res. 635:125–129.
Ruckstuhl, L., Beretz, A., Anton, R., and Laudry, Y. 1979. Flavonoids are selective cyclic GMP phosphoiesterase inhibitors. Biochem. Pharmacol. 28:535–538.
Cushman, M., Nagarathnam, D., Burg, D. L., and Gearhlen, R. L. 1991. Synthesis and protein-tyrosine kinase inhibitory activities of flavonoids analogues. J. Med. Chem. 34:798–806.
Ferriola, P. C., Coy, V., and Middleton, E. 1989. Protein kinase C inhibition by flavonoids. Kinetics mechanisms and structure-activity relationships. Biochem. Pharmacol. 38:245–254.
Koch, H. P., Jager, W., Groh, U., an Plank, G. 1992. In vitro inhibition of adenosine deaminase by flavonoids and related compounds. Meth. Fin. Exp. Clin. Pharmacol. 14:413–417.
Ji, X., Melman, N., and Jacobson, K. A. 1996. Interactions of flavonoids and other phytochemicals with adenosine receptors. J. Med. Chem. 39:781–788.
Nielsen, M., Frokjaer, S., and Braestrup, C. 1988. High affinity of naturally-occurring biflavonoid, amentoflavone, to brain benzodiazepine receptors in vitro. Biochem. Pharmacol. 37:3285–3287.
Medina, J. H., Peña, C., Levi M., Wolfman, C., and Paladini A. C. 1989. Benzodiazepine-like molecules as well as other ligands for the brain benzodiazepine receptor are relatively common constituents of plantas. Biochem. Biophys. Res. Comm. 165:547–553.
Luck, K. C., Stern, L., Weigele, M., O'Brien, R. A., and Spirst, N. 1983. Isolation and identification of “diazepam-like” compounds from bovine urine. J. Nat. Prod. 46:852–861.
Medina, J. H., Danelon, J. L., Wasowski, C., Levi de Stein, M., and Paladini, A. C. 1991. Production of benzodiazepine-like molecules in bovine rumen. Biochem. Biophys. Res. Comm. 181:1048–1055.
Medina, J. H., Paladini A. C., Wolfman, C. Levi, M., Calvo, D., Diaz, L., and Peña, C. 1990 Chrysin (5,7 di-OH flavone) a naturally-occurring ligand for benzodiazepine receptors, with anticonvulsant properties. Biochem. Pharmacol. 40:2227–2232.
Wolfman, C. Viola, H. Paladini, A. C. Dajas, F., and Medina, J. H. 1994. Possible anxiolytic effects of chrysin, a central benzodiazepine receptor ligand isolated from Passiflora coerulea. Pharmacol. Biochem. Behav 47:1–4.
Viola, H., Wasowski, C., Levi, M., Wolfman, C. Silveira, R., Dajas, F. Medina, J. H., and Paladini, A. C. 1995. Apigenin, a component of Matricaria recutita flowers is a central benzodiazepine receptors-ligand with anxiolytic effects. Planta Med. 61:213–216.
Wei, H., Tye, L., Bresnick, E., and Birt D. F. 1990. Inhibitory effect of apigenin, a plant flavonoid, on epidermal ornithine decarboxylase and skin tumor promotion in mice. Cancer Res. 50:499–502.
Okuyama, E., Okamoto, Y., Yamazaki, M., and Satake, M. 1996. Pharmacologically active components of a peruvian medicinal plant, Huanarpo (Jatropha cilliata, M. Arg.) Chem. Pharm. Bull. (Japan). 44:333–336.
Viola, H., Wolfman, C., Levi, M., Wasowski, C., Peña, C., Medina, J. H., and Paladini, A. C. 1994. Isolation of pharmacologically active benzodiazepine receptor ligands from Tilia tomentosa (Tiliaceae). J. Ethnophamacol. 44:47–53.
Marder, M., Viola, H., Wasowski, C., Wolfman, C., Waterman, P. G., Medina, J. H., and Paladini, A. C. 1996. Cirsiliol and caffeic acid ethyl ester isolated from Salvia guaranitica, are competitive ligands for the central benzodiazepine receptors. Phytomedicine 3:29–31.
Haberlein, H., Tschiersch, K. P., and Schafer, H. L. 1994. Flavonoids from Leptospermum scoparium with affinity to the benzodiazepine receptor characterized by structure activity relationships and in vivo studies of a plant extract. Pharmazie 49:912–921.
Shen, X.-L., Nielsen, M., Witt, M. R., Sterner, O., Bergendorff, O., and Khayyal, M. 1994. Inhibition of [methyl-3H] diazepam binding to rat brain membranes in vitro by dinatin and skrofulein. Acta Pharmacol. Sinica 15:385–388.
Marder, M., Viola, H., Wasowski, C., Wolfman, C. Waterman, P., Medina, J. H., and Paladini, A. C. 1995. 6,3'-dinitroflavone, a novel high affinity ligand for the benzodiazepine receptor with potent anxiolytic properties. Bioorg. & Med. Chem. Lett. 5:2717–2720.
Sternbach, L. H. 1978. The benzodiazepine story. Prog. Drug Res. 22:229–266.
Marder, M., Viola, H., Wasowski, C., Wolfman, C., Waterman, P., Cassels, B. K., Medina, J. H., and Paladini, A. C. 1996. 6 Bromoflavone, a high affinity ligand for the benzodiazepine receptors is a member of a family of active flavonoids. Biochem. Biophys. Res. Comm., in press.
Lopez, F., Miller, L. G., Greenblatt, D. J., Kaplan, G. B., and Shader, R. I. 1989. Interaction of caffeine with the GABAA receptor complex: alterations in receptor function but not ligand binding. Eur. J. Pharmacol. 172:453–459.
Cammarota, M. C., Wolfman, C., Jerusalinsky, D., Bernabeu, R., Levi, M., Izquierdo, I., and Medina, J. H. 1995. Inhibitory avoidance training-induced selective changes in 3H-AMPA receptor binding in the hippocamal formation. Neurobiol. Learn. and Mem. 64:257–264.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Medina, J.H., Viola, H., Wolfman, C. et al. Overview—Flavonoids: A New Family of Benzodiazepine Receptor Ligands. Neurochem Res 22, 419–425 (1997). https://doi.org/10.1023/A:1027303609517
Issue Date:
DOI: https://doi.org/10.1023/A:1027303609517